Postprocedural outcome according to the VARC-2 criteria
| OPN first to third quartile (n=163) | OPN fourth quartile (n=54) | p Value | |
| 30-day mortality | 9 (5.52%) | 6 (11.11%) | 0.212 |
| VARC-2 myocardial infarction | 3 (1.8%) | 1 (1.9%) | 0.996 |
| VARC-2 stroke | 8 (4.5%) | 1 (1.9%) | 0.457 |
| VARC-2 disabling stroke | 5 (3.1%) | 0 | 0.335 |
| VARC-2 bleeding | 23 (14.1%) | 13 (24.1%) | 0.095 |
| VARC-2 life-threatening bleeding | 6 (3.7%) | 2 (3.7%) | 1.000 |
| VARC-2 major bleeding | 10 (6.1%) | 10 (18.5%) | 0.012 |
| VARC-2 acute kidney injury | 4 (2.5%) | 7 (13.0%) | 0.006 |
| VARC-2 acute kidney injury stage 3 | 1 (0.6%) | 5 (9.3%) | 0.004 |
| VARC-2 vascular complications | 22 (13.5%) | 9 (16.7%) | 0.654 |
| VARC-2 major vascular complications | 3 (1.8%) | 1 (1.9%) | 1.000 |
| VARC-2 persistent high-degree AV block | 9 (5.5%) | 3 (5.6%) | 1.000 |
| VARC-2 pacemaker implantation | 11 (6.7%) | 5 (9.3%) | 0.306 |
| VARC-2 conversion to open surgery | 1 (0.6%) | 1 (1.9%) | 0.437 |
| VARC-2 TAVI-in-TAVI deployment | 5 (3.1%) | 4 (7.4%) | 0.231 |
| Valve regurgitation post TAVI | 0.204 | ||
| 0 | 61 (37.42%) | 18 (33.33%) | |
| I | 78 (47.85%) | 30 (55.56%) | |
| II | 24 (14.72%) | 5 (9.26%) | |
| III | 0 | 1 (1.85%) |
AV, atrioventricular; OPN, osteopontin; TAVI, transcatheter aortic valve implantation; VARC-2, Valve Academic Research Consortium-2.